Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Mallinckrodt
McKinsey
Merck
AstraZeneca

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Vedolizumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Vedolizumab: Sponsors, patents, clinical trial progress

Vedolizumab is an investigational drug.

There have been 66 clinical trials for Vedolizumab. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2015.

The most common disease conditions in clinical trials are Colitis, Ulcerative, Crohn Disease, and Colitis. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and Icahn School of Medicine at Mount Sinai.

There are fifteen US patents protecting this investigational drug and four hundred and fifty-five international patents.

Recent Clinical Trials for Vedolizumab
TitleSponsorPhase
Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease (GvHD) After Allogenic Stem-cell Transplantation (HSCT)The Swedish Research CouncilPhase 1/Phase 2
Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease (GvHD) After Allogenic Stem-cell Transplantation (HSCT)Mats RembergerPhase 1/Phase 2
NIR FME of Labelled Vedolizumab to Elucidate the Mechanism of Action and Predicting Response in IBD Patients.University Medical Center GroningenPhase 1

See all Vedolizumab clinical trials

Clinical Trial Summary for Vedolizumab

Top disease conditions for Vedolizumab
Top clinical trial sponsors for Vedolizumab

See all Vedolizumab clinical trials

US Patents for Vedolizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Vedolizumab   Start Trial Methods of treating ulcerative colitis MILLENNIUM PHARMACEUTICALS, INC. (Cambridge, MA)   Start Trial
Vedolizumab   Start Trial Formulation for anti-.alpha.4.beta.7 antibody Millennium Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Vedolizumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Vedolizumab   Start Trial Methods of treating ulcerative colitis Millennium Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Vedolizumab   Start Trial Method of treating an inflammatory bowel disease comprising agonists of orexin-1 receptor INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE PARIS DIDEROT--PARIS 7 (Paris, FR) ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR)   Start Trial
Vedolizumab   Start Trial Substituted dihydropyrrolopyrazole derivative UBE INDUSTRIES, LTD. (Yamaguchi, JP)   Start Trial
Vedolizumab   Start Trial Gene editing methods and compositions for eliminating risk of JC virus activation and PML (progressive multifocal leukoencephalopathy) during immunosuppressive therapy Excision BioTherapeutics, Inc. (Bedminster, unknown) Temple University of the Commonwealth System of Higher Education (Philadelphia, unknown)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Vedolizumab

Drugname Country Document Number Estimated Expiration Related US Patent
Vedolizumab Argentina 086237 2031-05-02   Start Trial
Vedolizumab Australia 2012250873 2031-05-02   Start Trial
Vedolizumab Australia 2016231469 2031-05-02   Start Trial
Vedolizumab Australia 2018278866 2031-05-02   Start Trial
Vedolizumab Australia 2019201926 2031-05-02   Start Trial
Vedolizumab Canada 2834867 2031-05-02   Start Trial
Vedolizumab Canada 3028209 2031-05-02   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
AstraZeneca
Baxter
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.